CompletedPHASE1, PHASE2NCT01486446
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Studying Primary erythromelalgia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xenon Pharmaceuticals Inc.
- Principal Investigator
- Almena L Free, MDPinnacle Research Group LLC.
- Intervention
- XPF-002(drug)
- Enrollment
- 8 target
- Eligibility
- 19-80 years · All sexes
- Timeline
- 2011 – 2012
Study locations (1)
- Pinnacle Research Group, LLC., Anniston, Alabama, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01486446 on ClinicalTrials.govOther trials for Primary erythromelalgia
Additional recruiting or active studies for the same condition.